Brian Bonilla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Brian Bonilla has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Azza H. Idris
Vaccine Research Center, National Institutes of Health 2 , Bethesda, MD
4 shared publications - Eric Calvo
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
4 shared publications - Marlon Dillon
Vaccine Research Center, National Institutes of Health 2 , Bethesda, MD
4 shared publications - Robert A. Seder
Vaccine Research Center, National Institutes of Health 2 , Bethesda, MD
4 shared publications - Joseph R. Francica
Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA
3 shared publications - Paola Carolina Valenzuela-Leon
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
3 shared publications
Latest Publications
- Open Access
Chromosome-Level Genome of Simulium vittatum Links Black Fly Cytogenetics to Genome Organization and Evolution
Black flies (Diptera: Simuliidae) are important vectors of pathogens affecting human and animal health, yet the absence of a chromosome-level nuclear reference genome has constrained molecular and evolutionary studies of the family. Here, we present the first chromosome-level nuclear genome and a developmental transcriptomic resource for the long-established IS-7 laboratory lineage of Simulium vittatum . Combining Oxford Nanopore long-read sequencing with Hi-C scaffolding, we assembled a 340.4-Mb genome, with 99.1% of the assembly resolved into three chromosome-length scaffolds (N50=104.8 Mb, BUSCO completeness 93.9%), consistent with the known 2n = 6 karyotype. Using the historically mapped molecular landmarks SVAT and SVEP, we assigned the two arms of chromosome III as IIIS and IIIL, respectively, linking sequence coordinates to the classical polytene chromosome map. Repetitive DNA comprises 46.48% of the assembly, including 29.68% unclassified repeats, and annotation identified 14,732 protein-coding genes and 16,417 transcripts. This reference genome connects classical black fly cytogenetics with sequence-level analyses of genome organization, structural variation, and gene content, addressing a major genomic gap within Culicomorpha and providing a foundation for comparative studies of chromosome evolution, hematophagy, and vector biology across Simuliidae.
Open AccessChromosome-Level Genome of Simulium vittatum Links Black Fly Cytogenetics to Genome Organization and Evolution
Black flies (Diptera: Simuliidae) are important vectors of pathogens affecting human and animal health, yet the absence of a chromosome-level nuclear reference genome has constrained molecular and evolutionary studies of the family. Here, we present the first chromosome-level nuclear genome and a developmental transcriptomic resource for the long-established IS-7 laboratory lineage of Simulium vittatum . Combining Oxford Nanopore long-read sequencing with Hi-C scaffolding, we assembled a 340.4-Mb genome, with 99.1% of the assembly resolved into three chromosome-length scaffolds (N50=104.8 Mb, BUSCO completeness 93.9%), consistent with the known 2n = 6 karyotype. Using the historically mapped molecular landmarks SVAT and SVEP, we assigned the two arms of chromosome III as IIIS and IIIL, respectively, linking sequence coordinates to the classical polytene chromosome map. Repetitive DNA comprises 46.48% of the assembly, including 29.68% unclassified repeats, and annotation identified 14,732 protein-coding genes and 16,417 transcripts. This reference genome connects classical black fly cytogenetics with sequence-level analyses of genome organization, structural variation, and gene content, addressing a major genomic gap within Culicomorpha and providing a foundation for comparative studies of chromosome evolution, hematophagy, and vector biology across Simuliidae.
- Open Access
- 4 September 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (10)
The black fly salivary protein Simukunin inhibits complement activation through the lectin pathway protease MASP-2
- 4 September 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (10)
Open AccessThe black fly salivary protein Simukunin inhibits complement activation through the lectin pathway protease MASP-2
- Open Access
- 25 March 2026
- Published by Springer Nature in BMC Genomics
- Vol. 27 (1)
Chromosome-scale genome assembly and developmental transcriptome of Aedes triseriatus, vector of La Crosse virus
Background: Aedes triseriatus is an endemic North American mosquito and the primary vector of La Crosse virus, the etiologic agent of La Crosse encephalitis. This neuroinvasive disease is the leading cause of arboviral encephalitis in the United States and disproportionately affects pediatric populations. Despite its medical importance, the genomic architecture and vectorial capacity of A. triseriatus remain incompletely understood. Results: We generated a chromosome-scale genome assembly and developmental transcriptome for A. triseriatus using an integrated approach combining PacBio long-read sequencing, Hi-C scaffolding, and Illumina sequencing technologies. The final assembly spans approximately 2.4 Gb, representing the largest mosquito genome reported to date, and consists of chromosome-sized scaffolds supported by Hi-C data and manual curation. Transcriptome profiling across larvae, pupae, and adult males and females revealed dynamic, stage-specific gene expression patterns associated with distinct physiological processes. Conclusions: These genomic and transcriptomic resources provide a comprehensive foundation for investigating the molecular basis of La Crosse virus transmission, mosquito development, and vector–host interactions in A. triseriatus . The chromosome-scale assembly establishes an essential framework for future functional, evolutionary, and vector biology studies in this medically important species.
- 25 March 2026
- Published by Springer Nature in BMC Genomics
- Vol. 27 (1)
Open AccessChromosome-scale genome assembly and developmental transcriptome of Aedes triseriatus, vector of La Crosse virus
Background: Aedes triseriatus is an endemic North American mosquito and the primary vector of La Crosse virus, the etiologic agent of La Crosse encephalitis. This neuroinvasive disease is the leading cause of arboviral encephalitis in the United States and disproportionately affects pediatric populations. Despite its medical importance, the genomic architecture and vectorial capacity of A. triseriatus remain incompletely understood. Results: We generated a chromosome-scale genome assembly and developmental transcriptome for A. triseriatus using an integrated approach combining PacBio long-read sequencing, Hi-C scaffolding, and Illumina sequencing technologies. The final assembly spans approximately 2.4 Gb, representing the largest mosquito genome reported to date, and consists of chromosome-sized scaffolds supported by Hi-C data and manual curation. Transcriptome profiling across larvae, pupae, and adult males and females revealed dynamic, stage-specific gene expression patterns associated with distinct physiological processes. Conclusions: These genomic and transcriptomic resources provide a comprehensive foundation for investigating the molecular basis of La Crosse virus transmission, mosquito development, and vector–host interactions in A. triseriatus . The chromosome-scale assembly establishes an essential framework for future functional, evolutionary, and vector biology studies in this medically important species.
- 23 April 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (795) , eadk6745
FcγR binding differentially contributes to protection by two human monoclonal antibodies targeting Plasmodium falciparum circumsporozoite protein
Antibodies mediate protection against a wide range of pathogens through binding and neutralizing the pathogen or through Fc-mediated effector functions. Human monoclonal antibodies (mAbs) CIS43LS and L9LS show high-affinity binding targeting distinct regions on the Plasmodium falciparum circumsporozoite protein (PfCSP) and are highly effective in preventing malaria in humans. However, the role of FcγR binding in protection by these mAbs has not been determined. Here, we assessed several Fc variants of CIS43LS and L9LS for protection against infection with transgenic Plasmodium berghei parasite expressing PfCSP in mice. Limiting binding to FcγRs did not reduce protection compared to the parental mAbs in mice. To determine whether protection could be improved in vivo by Fc modification, we engineered Fc variant mAbs with increased binding to distinct FcγRs. Passive transfer of CIS43LS-DE and CIS43LS-DEAL variants resulted in an approximately two- to threefold reduction in the liver-stage parasite burden in C57BL/6 or human FcγR mice compared with the parental CIS43LS after challenge. CIS43LS-DEAL also enhanced protection of mice after mosquito bite challenge. Systems serology analysis revealed that the CIS43LS-DE and CIS43LS-DEAL variants could enhance human neutrophil and monocyte phagocytosis, as well as NK cell activation, compared with CIS43LS. However, similar Fc modifications incorporated into L9LS did not increase protection compared to the parental mAb. Overall, although FcγR binding by CIS43LS and L9LS is dispensable in mouse models of malaria, enhancing the binding of CIS43LS to FcγR showed a modest increase in the potency of this mAb.
- 23 April 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (795) , eadk6745
FcγR binding differentially contributes to protection by two human monoclonal antibodies targeting Plasmodium falciparum circumsporozoite protein
Antibodies mediate protection against a wide range of pathogens through binding and neutralizing the pathogen or through Fc-mediated effector functions. Human monoclonal antibodies (mAbs) CIS43LS and L9LS show high-affinity binding targeting distinct regions on the Plasmodium falciparum circumsporozoite protein (PfCSP) and are highly effective in preventing malaria in humans. However, the role of FcγR binding in protection by these mAbs has not been determined. Here, we assessed several Fc variants of CIS43LS and L9LS for protection against infection with transgenic Plasmodium berghei parasite expressing PfCSP in mice. Limiting binding to FcγRs did not reduce protection compared to the parental mAbs in mice. To determine whether protection could be improved in vivo by Fc modification, we engineered Fc variant mAbs with increased binding to distinct FcγRs. Passive transfer of CIS43LS-DE and CIS43LS-DEAL variants resulted in an approximately two- to threefold reduction in the liver-stage parasite burden in C57BL/6 or human FcγR mice compared with the parental CIS43LS after challenge. CIS43LS-DEAL also enhanced protection of mice after mosquito bite challenge. Systems serology analysis revealed that the CIS43LS-DE and CIS43LS-DEAL variants could enhance human neutrophil and monocyte phagocytosis, as well as NK cell activation, compared with CIS43LS. However, similar Fc modifications incorporated into L9LS did not increase protection compared to the parental mAb. Overall, although FcγR binding by CIS43LS and L9LS is dispensable in mouse models of malaria, enhancing the binding of CIS43LS to FcγR showed a modest increase in the potency of this mAb.
- Top Cited Papers
- 3 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 387 (6729) , eadr0510
Protective antibodies target cryptic epitope unmasked by cleavage of malaria sporozoite protein
The most advanced monoclonal antibodies (mAbs) and vaccines against malaria target the central repeat region or closely related sequences within the Plasmodium falciparum circumsporozoite protein (PfCSP). Here, using an antigen-agnostic strategy to investigate human antibody responses to whole sporozoites, we identified a class of mAbs that target a cryptic PfCSP epitope that is only exposed after cleavage and subsequent pyroglutamylation (pGlu) of the newly formed N terminus. This pGlu-CSP epitope is not targeted by current anti-PfCSP mAbs and is not included in the licensed malaria vaccines. MAD21-101, the most potent mAb in this class, confers sterile protection against Pf infection in a human liver–chimeric mouse model. These findings reveal a site of vulnerability on the sporozoite surface that can be targeted by next-generation antimalarial interventions.
- 3 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 387 (6729) , eadr0510
Top Cited PapersProtective antibodies target cryptic epitope unmasked by cleavage of malaria sporozoite protein
The most advanced monoclonal antibodies (mAbs) and vaccines against malaria target the central repeat region or closely related sequences within the Plasmodium falciparum circumsporozoite protein (PfCSP). Here, using an antigen-agnostic strategy to investigate human antibody responses to whole sporozoites, we identified a class of mAbs that target a cryptic PfCSP epitope that is only exposed after cleavage and subsequent pyroglutamylation (pGlu) of the newly formed N terminus. This pGlu-CSP epitope is not targeted by current anti-PfCSP mAbs and is not included in the licensed malaria vaccines. MAD21-101, the most potent mAb in this class, confers sterile protection against Pf infection in a human liver–chimeric mouse model. These findings reveal a site of vulnerability on the sporozoite surface that can be targeted by next-generation antimalarial interventions.
- Open Access
- 23 June 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (8)
Highly protective antimalarial antibodies via precision library generation and yeast display screening
The monoclonal antibody CIS43 targets the Plasmodium falciparum circumsporozoite protein (PfCSP) and prevents malaria infection in humans for up to 9 mo following a single intravenous administration. To enhance the potency and clinical utility of CIS43, we used iterative site-saturation mutagenesis and DNA shuffling to screen precise gene-variant yeast display libraries for improved PfCSP antigen recognition. We identified several mutations that improved recognition, predominately in framework regions, and combined these to produce a panel of antibody variants. The most improved antibody, CIS43_Var10, had three mutations and showed approximately sixfold enhanced protective potency in vivo compared to CIS43. Co-crystal and cryo-electron microscopy structures of CIS43_Var10 with the peptide epitope or with PfCSP, respectively, revealed functional roles for each of these mutations. The unbiased site-directed mutagenesis and screening pipeline described here represent a powerful approach to enhance protective potency and to enable broader clinical use of antimalarial antibodies.
- 23 June 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (8)
Open AccessHighly protective antimalarial antibodies via precision library generation and yeast display screening
The monoclonal antibody CIS43 targets the Plasmodium falciparum circumsporozoite protein (PfCSP) and prevents malaria infection in humans for up to 9 mo following a single intravenous administration. To enhance the potency and clinical utility of CIS43, we used iterative site-saturation mutagenesis and DNA shuffling to screen precise gene-variant yeast display libraries for improved PfCSP antigen recognition. We identified several mutations that improved recognition, predominately in framework regions, and combined these to produce a panel of antibody variants. The most improved antibody, CIS43_Var10, had three mutations and showed approximately sixfold enhanced protective potency in vivo compared to CIS43. Co-crystal and cryo-electron microscopy structures of CIS43_Var10 with the peptide epitope or with PfCSP, respectively, revealed functional roles for each of these mutations. The unbiased site-directed mutagenesis and screening pipeline described here represent a powerful approach to enhance protective potency and to enable broader clinical use of antimalarial antibodies.
- Open Access
- 6 December 2021
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 17 (12) , e1010133
Protective effects of combining monoclonal antibodies and vaccines against the Plasmodium falciparum circumsporozoite protein
Combinations of monoclonal antibodies (mAbs) against different epitopes on the same antigen synergistically neutralize many viruses. However, there are limited studies assessing whether combining human mAbs against distinct regions of thePlasmodium falciparum(Pf) circumsporozoite protein (CSP) enhancesin vivoprotection against malaria compared to each mAb alone or whether passive transfer of PfCSP mAbs would improve protection following vaccination against PfCSP. Here, we isolated a panel of human mAbs against the subdominant C-terminal domain of PfCSP (C-CSP) from a volunteer immunized with radiation-attenuated Pf sporozoites. These C-CSP-specific mAbs had limited binding to sporozoitesin vitrothat was increased by combination with neutralizing human “repeat” mAbs against the NPDP/NVDP/NANP tetrapeptides in the central repeat region of PfCSP. Nevertheless, passive transfer of repeat- and C-CSP-specific mAb combinations did not provide enhanced protection againstin vivosporozoite challenge compared to repeat mAbs alone. Furthermore, combining potent repeat-specific mAbs (CIS43, L9, and 317) that respectively target the three tetrapeptides (NPDP/NVDP/NANP) did not provide additional protection againstin vivosporozoite challenge. However, administration of either CIS43, L9, or 317 (but not C-CSP-specific mAbs) to mice that had been immunized with R21, a PfCSP-based virus-like particle vaccine that induces polyclonal antibodies against the repeat region and C-CSP, provided enhanced protection against sporozoite challenge when compared to vaccine or mAbs alone. Collectively, this study shows that while combining mAbs against the repeat and C-terminal regions of PfCSP provide no additional protectionin vivo, repeat mAbs do provide increased protection when combined with vaccine-induced polyclonal antibodies. These data should inform the implementation of PfCSP human mAbs alone or following vaccination to prevent malaria infection.
- 6 December 2021
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 17 (12) , e1010133
Open AccessProtective effects of combining monoclonal antibodies and vaccines against the Plasmodium falciparum circumsporozoite protein
Combinations of monoclonal antibodies (mAbs) against different epitopes on the same antigen synergistically neutralize many viruses. However, there are limited studies assessing whether combining human mAbs against distinct regions of thePlasmodium falciparum(Pf) circumsporozoite protein (CSP) enhancesin vivoprotection against malaria compared to each mAb alone or whether passive transfer of PfCSP mAbs would improve protection following vaccination against PfCSP. Here, we isolated a panel of human mAbs against the subdominant C-terminal domain of PfCSP (C-CSP) from a volunteer immunized with radiation-attenuated Pf sporozoites. These C-CSP-specific mAbs had limited binding to sporozoitesin vitrothat was increased by combination with neutralizing human “repeat” mAbs against the NPDP/NVDP/NANP tetrapeptides in the central repeat region of PfCSP. Nevertheless, passive transfer of repeat- and C-CSP-specific mAb combinations did not provide enhanced protection againstin vivosporozoite challenge compared to repeat mAbs alone. Furthermore, combining potent repeat-specific mAbs (CIS43, L9, and 317) that respectively target the three tetrapeptides (NPDP/NVDP/NANP) did not provide additional protection againstin vivosporozoite challenge. However, administration of either CIS43, L9, or 317 (but not C-CSP-specific mAbs) to mice that had been immunized with R21, a PfCSP-based virus-like particle vaccine that induces polyclonal antibodies against the repeat region and C-CSP, provided enhanced protection against sporozoite challenge when compared to vaccine or mAbs alone. Collectively, this study shows that while combining mAbs against the repeat and C-terminal regions of PfCSP provide no additional protectionin vivo, repeat mAbs do provide increased protection when combined with vaccine-induced polyclonal antibodies. These data should inform the implementation of PfCSP human mAbs alone or following vaccination to prevent malaria infection.
- Open Access
- 1 January 2021
- Published by Elsevier in Current Research in Structural Biology
- Vol. 3, 95-105
The structures of two salivary proteins from the West Nile vector Culex quinquefasciatus reveal a beta-trefoil fold with putative sugar binding properties
- 1 January 2021
- Published by Elsevier in Current Research in Structural Biology
- Vol. 3, 95-105
Open AccessThe structures of two salivary proteins from the West Nile vector Culex quinquefasciatus reveal a beta-trefoil fold with putative sugar binding properties